大肠癌组织中多药耐药基因的表达及意义  

Expression and significance of multidrug resistance gene in the colorectal cancer tissues

作　　者：卢志红 庞敏红 

机构地区：[1]张家口市第五医院 [2]张家口市第二医院,河北张家口075000

出　　处：《海南医学院学报》2015年第11期1584-1586,共3页Journal of Hainan Medical University

基　　金：河北省科学技术成果获奖项目(20122101)~~

摘　　要：目的:探讨大肠癌组织中多药耐药基因MDR1/P-gp与CerbB-2表达的相关性及临床意义。方法:选取86例大肠癌组织标本,采用免疫组化S-P法检测P-gp与CerbB-2的表达情况,并分析其相关性。结果:MDR1/P-gp与CerbB-2表达阳性率分别为36%(31/86)、28%(24/86);临床分期Ⅲ期大肠癌组织中CerbB-2阳性表达率显著高于Ⅰ、Ⅱ级(P<0.05);有腋窝淋巴结转移的大肠癌组织中MDR1/P-gp、CerbB-2的表达率明显高于无腋窝淋巴结转移大肠癌组织(P<0.05);P-gp蛋白阳性表达组CerbB-2阳性者占75.5%(37/49),CerbB-2阴性者占24.48%(12/49),两者差异有统计学意义(P<0.01);P-gp与CerbB-2的阳性表达率间具有一定正相关性。结论:P-gp与CerbB-2基因在大肠癌多药耐药发生中起一定作用,其表达具有相关性,联合检测可为大肠癌化疗方案选择提供依据。Objective： To explore the correlation of expressions of MDR1/P-gp and CerbB-2 in the colorectal cancer tissues and their clinical significance. Methods： A total of 86 colorectal cancer tissues specimens were included in the study. The immunohistochemical S-P method was used to detect the expressions of P-gp and CerbB-2, and their correlations were ana- lyzed. Results： The positive rates of the expressions of MDR1/P-gp and CerbB-2 were 36% （31/86） and 28% （24/86）, respectively. The positive expression rate of CerbB-2 in the colorectal cancer tissues at a clinical stage of III was significantly higher than that at stage I and II （P〈0.05）. The positive expression rates of MDR1/P-gp and CerbB-2 in the colorectal cancer tissues with axillary lymph node metastasis were significantly higher than those in the tissues without axillary lymph node metastasis （P〈0.05）. In the P-gp positive expression group, the positive rate of CerbB-2 was 75.5% （37/49）, while the negative rate of CerbB-2 was 24.48% （12/49）, and the difference was statistically significant （P〈0.01）. P-gp had a certain positive correlation with the positive expression rate of CerbB-2. Conclusions： P-gp and CerbB-2 play a certain role in the occur- rence of multidrug resistance of colorectal cancer, and their expressions are correlated; therefore, the combination detection can provide an evidence for the chemotherapy choice of colorectal cancer.

关 键 词：MDR1/P-GP CERBB-2 大肠癌 

分 类 号：R735.34[医药卫生—肿瘤]